Lyell Immunopharma financials
$9.63−1.13%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0K | $2.0K | $6.0K | $15.0K | $8.0K | $7.0K | $11.0K | $34.0K | $13.0K | $3.0K | $13.0K | $25.0K |
| Gross profit | $4.0K | $2.0K | $6.0K | $15.0K | $8.0K | $7.0K | $11.0K | $34.0K | $13.0K | $3.0K | $13.0K | $25.0K |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$47.3M | -$44.3M | -$129.8M | -$37.3M | -$47.1M | -$57.4M | -$204.5M | -$50.5M | -$51.5M | -$56.7M | -$59.5M | -$59.0M |
| Net income | -$44.8M | -$24.2M | -$140.7M | -$38.8M | -$42.7M | -$52.2M | -$191.9M | -$44.6M | -$45.8M | -$60.7M | -$52.9M | -$50.9M |
| Net margin | −1118875.0% | −1207650.0% | −2345383.3% | −258973.3% | −533550.0% | −745642.9% | −1744863.6% | −131126.5% | −352376.9% | −2022233.3% | −407153.8% | −203412.0% |
| Diluted EPS | $-1.92 | $-1.10 | $-6.85 | $-2.13 | $-2.89 | $-3.54 | $-5.01 | $-3.48 | $-3.59 | $-4.80 | $-4.19 | $-4.00 |
| EBITDA | -$45.1M | -$41.9M | -$61.1M | -$34.7M | -$42.6M | -$53.9M | -$60.9M | -$45.8M | -$46.6M | -$51.6M | -$54.5M | -$53.9M |
| Operating cash flow | -$33.9M | -$38.5M | -$32.3M | -$28.6M | -$34.5M | -$54.7M | -$47.2M | -$35.0M | -$38.1M | -$42.0M | -$40.6M | -$37.7M |
| Free cash flow | -$34.2M | -$38.6M | -$32.6M | -$28.6M | -$34.6M | -$55.0M | -$47.3M | -$35.1M | -$38.4M | -$42.0M | -$40.7M | -$37.9M |
| Diluted shares | 23.4M | 21.9M | 20.6M | 18.3M | 14.8M | 14.8M | 38.3M | 12.8M | 12.8M | 12.7M | 12.6M | 12.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $73.0M | $90.8M | $60.2M | $123.6M | $98.8M | $120.3M |
| Short-term investments | $131.1M | $163.3M | $187.0M | $196.0M | $178.0M | $180.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $311.2M | $350.6M | $340.1M | $408.0M | $385.5M | $429.8M |
| Total liabilities | $77.3M | $77.0M | $91.8M | $78.8M | $86.5M | $93.3M |
| Shareholders' equity | $233.8M | $273.7M | $248.2M | $329.1M | $298.9M | $336.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology